β-Lapachone (LAP), an FDA-approved small molecule, targets NAD(P)H: quinone oxidoreductase-1 (NQO1), which overexpressed in cancer cells (5–200 × higher than in normal tissues) [35,36]. The gene discussed is NQO1; the disease is cancer.